Member Info for amones

Inclusion of Hutchmed shares (13.HK) to Hong Kong composite index and certain other indexes on this Monday could be the reason for the improvement in the sp over the last two weeks. Particularly of interest is the improved volume (and sp!) during the last 3-4 trading hours at HKSE. As per the information on HKEX official site, in the very last minute, 236,000 shares were traded at HKD 65.70. Perhaps an early sign of institutional interest? Or, is it something to do with the north bound / south bound connect program? Or, both? Are Asian fund managers obliged to deal with stocks present on certain indexes only? If so, certainly a welcome news for all longtimers.
Interested to know fellow posters’ opinions and observations.
GLA.
(DYOR. No recommendation intended)

SS,
It is single amount of market cap quoted in three different currencies.
on 31/8/21, there were 864,367,280 HK listed shares, equivalent to 864,367,280 AIM shares, equivalent to 172,873,456 American depositary shares traded on Nasdaq.

Can not see any valuation numbers in that RNS. Is there a typo while quoting £70 per share, by next year? £7.00 would be a much more acceptable number in real world!

Waiting to see any positive impact on the sp happening following the addition of HCM shares (13.hk) to certain index/es in Hong Kong on 5th September. GLA.

Thank you both

Jatw, I am getting confused. What exactly is supposed to be happening on Monday, 6th September, the date mentioned in the news release by the company? Is it the date on which 0013.HK being added to one or the other index? (From Davey’s post above; presence on similar indexes might facilitate flurry of institutional buyers, which is a welcome prospect).

Thank you both for explaining the collaboration with Epizyme. It appears enough background work been done about synergy with the candidates in Hutchmed’s pipeline. That is what CEO has expressed during the conference call.

Jatw,
‘Three legged stool’ -a nice description indeed for the present form of hutchmed. It used to be a two legged ladder, often, quite wobbly! The recently added additional leg (HKSE listing) has converted hcm to a more stable ‘Three legged stool’. Hopefully, a forthcoming fourth leg (either a STAR market listing or HKSE stock connect) will make it a more comfortable, if not a luxurious, high back chair!

Thanks Jatw for the reassuring information.
Is CH’s interview available online to watch?

SS, Thanks for your post.
Curious to know the implications of such delisting. If the analyst’s opinions are correct about ADRs delisting, will there be a forced sell-off? In fact, ADRs sp went up during the last trading day at NYSE.
Davey, you had posted in the past about your interest in HCM ADRs. Are you feeling concerned about this information?

Middleman making a killing from the “fully fungible” nature. Buying at a price one GBP cheaper in London and then selling the same night at HK??

Davey,
I think its time for you to reconsider the year you have been quoting (2025) for the 20 billion valuation! Bring it closer!!

What events happened during weekend? I might have missed it.
Would China suppress its own pharmaceutical companies by not paying the correct prices for the medicines they produce? Such a strategy would be against the country's intention of becoming self-sufficient in the pharma sector.

Jatw, your last two posts here, are undoubtedly the best two posts of the week! You have collaborated all related factors and presented in a nice way. Thank you.

It is great to see daily trading volumes of over 1-2 million at Hk and few hundreds of thousands, both at LSE and NYSE, with the sp raising on a steady pace. There could be lot of interest among new investors. Market valuation of $7 billion for a pharma company of this kind might appear quite attractive. It is bit surprising that HCM is hardly getting any coverage in the financial sections of UK media. Has the magnificent run of the sp over the last 3 weeks gone unnoticed? It will be nice to know if any new institutional investors are building their stakes. If anyone finds any articles, please post mention here.

(Ps: no recommendation intended to buy or sell. Do your own research)

SS, I totally second your opinion regarding Davey.

It will be nice to read posts from newcomers to this board as it be helpful for all. I am sure private investors based in the UK are curious to know about the coverage 0013.hk is getting in the local media and press in HK.

On a day of ‘total silence’ here;

1. I don’t remember HCM stock ever managing to stay around or above the previous peak price seen in 2018, for three weeks running. Even on a day of mostly ‘red’ numbers every where else, HCM continues to shine blue. I am sure every longtime holder share a happy feeling for being around with this stock. Well done all!

Following the HK IPO, I tried to find a HK/ Asian shares chat forum, similar to this. My limited search didn’t show anything useful. On the other hand, there is a possibility a few, if not many, overseas investors interested and searching the net for information about Hutchmed, of following this chat forum for their reference. Well organised layout, easy to use links of LSE, well researched posts by Davey, jatw and others, decent and well mannered discussions among the members of this board (most importantly, completely free from bots!) are the reasons for me guessing so.
I believe Davey isn’t contemplating to retire from this board any time soon!

GS, tacly,
CPP invested $100m in November’20 paying $30 per ADS. This information is in the news section. We can scroll back on the news tab to see it. Subsequently, did they short sold all their holding except for a minority number of shares by 31st March? Is that source information quoted by external company reliable? During April and May, price of ADS was around $25. However, as per yesterday’s company news release. CPP are holding 26.8m ordinary shares.

Had a look at the news from November’20. CPP invested in 16.7 million ordinary shares at that time. As per today’s news, the number stands at 26.8 millions. The increase in CPP’s holding could be following ‘cornerstone investment’ during the recent HK IPO. Encouraging item of news indeed!

Even if it is reiteration of existing holding, such news will still be useful for HK based investors (as well as in the UK and USA) looking for information regarding involvement of major funds like CPP.

GS, have they increased their holding? Forgotten what percentage of shares CPP was holding following their initial investment/s.

Wondering if this investment from
Jean Eric Salata is a ‘new’ investment or just reiteration of existing holding by his firm. Anyhow, 3.6% of the total share capital is quite significant. It should get noticed by the market, if not already done.